Why This Patent News Is Big For Bristols Acquisition Of Celgene | Latest News RSS feed
Why This Patent News Is Big For Bristols Acquisition Of Celgene - Latest News
Thumbs-up on $74B BMS-Celgene deal ends months of activist outrage
why has Bristol Myers stock ... team…we believe that the acquisition of Celgene creates a leading company. It is the right transaction for Bristol-Myers Squibb.” Biopharma is a fast-growing world ... read more
Bristol-Myers Squibb As A Dividend Growth Investment
The following article will focus on a biopharmaceutical company — Bristol-Myers ... can only rise. Why buy now? Well, one reason is that the news of the Celgene acquisition has driven the ... read more
Is Biogen a Beat-Up Bargain? And Is Bristol-Myers' Mega-Merger on the Rocks?
Biogen's (NASDAQ:BIIB) bid to reshape Alzheimer's disease treatment was delivered a big blow last week when it decided to bail on its once-promising Alzheimer's drug aducanumab. The news ... if ... read more
Looking for another news?
Bristol-Celgene Deal Opposition Needs a Dose of Reality
(Bloomberg Opinion) -- Whispers of discontent around Bristol-Myers Squibb Co.’s $74 billion acquisition of Celgene Corp. have turned ... but is missing a compelling argument for exactly why that’s the ... read more
Serious business of cancer sparks Pharma M&A spree
The takeover comes days after US-based Bristol-Myers Squibb said it was buying biotech firm Celgene for $74bn ... of the most important therapy areas for it. So why has there been so much merger and ... read more
Bristol-Myers scores first big deal of 2019 with $74B buyout of oncology bigwig Celgene
The long-predicted deal-making boom in Big Pharma started with a bang on Wednesday, as Bristol-Myers Squibb announced it will buy Celgene in ... But the ever-present patent cliff in Big Pharma created ... read more
Celgene vs. Gilead Sciences: Who Reported Better Earnings?
There's not a lot of patent expiration risk associated with ... will it all be internal, will it be acquisition-driven, will it be collaborations? -- Celgene has been a big fan of collaborations. ... read more
Why a Pfizer Takeover of Bristol-Myers Squibb Seems Unlikely
growing our business on off-patent products. I think the key words there are "starting with our internal pipeline." Conclusion: Unless Kindler turns into Santa Claus over the holidays and suddenly ... read more
3 Reasons Bristol-Myers' $90 Billion Mega-Merger Makes It A Must Own Stock
Then Bristol would appeal which means that the earliest generic rivals could hit the market is 2021, just one year earlier than the patent expirations. What about the big ... This is why Bristol and ... read more
Why Big Pharma is finally discovering the Bay Area
Pharmaceutical companies for the past decade have faced a "patent cliff," where generic companies can develop lower-cost alternatives to the drugs that made Big Pharma rich ... thanks to acquisitions ... read more